Tianyin has received approval from the Chinese State Food and Drug Administration (SFDA) to produce Sanqi Tablets in dosage form of 0.5gm/tablet, and Yinqiao Jiedu Tablets in dosage form of 0.5gm/tablet.
Sanqi Tablets are a generic TCM that effectively treats traumatic injuries and stops bleeding without causing blood stasis, while also alleviates associated pain and reduces swelling. Sanqi is also used as a hemostatic for patients with internal bleeding or hemorrhagic diseases.
Yinqiao Jiedu Tablets are a generic TCM which are used mainly to treat acute respiratory system ailments, such as influenza and common cold. It is specifically used to clear the lungs and aid in function of the throat.
Mr. Jiang, chairman and CEO of Tianyin, said: We are very pleased to receive approvals for our Sanqi Tablets and Yinqiao Jiedu Tablets from the Chinese SFDA.
We will produce both drugs in our new facility which just passed Sichuan provincial FDA inspection, a key component of GMP certification, in July. We believe the facility meets all GMP standards and we expect to receive certification in the very near term, a milestone which will significantly increase our capacity and enable us to achieve our growth objectives, he added.